Prostatic Artery Embolization: Influence of Cone-Beam Computed Tomography on Radiation Exposure, Procedure Time, and Contrast Media Use

por Bürckenmeyer, F., Diamantis, I., Kriechenbauer, T., Lehmann, T., Franiel, T., Malouhi, A., Grimm, M. O., Teichgräber, U., Aschenbach, R.
Publicado 2021

Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma.

por Clasen, S., Schulz, W. A., Gerharz, C. D., Grimm, M. O., Christoph, F., Schmitz-Dräger, B. J.
Publicado 1998

Identification of high-risk patients with clear cell renal cell carcinoma based on interphase-FISH

por Sanjmyatav, J, Matthes, S, Muehr, M, Sava, D, Sternal, M, Wunderlich, H, Gajda, M, Grimm, M-O, Junker, K
Publicado 2014

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice

por Grivas, P., Grande, E., Davis, I.D., Moon, H.H., Grimm, M.-O., Gupta, S., Barthélémy, P., Thibault, C., Guenther, S., Hanson, S., Sternberg, C.N.
Publicado 2023

Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

por Tomita, Y., Larkin, J., Venugopal, B., Haanen, J., Kanayama, H., Eto, M., Grimm, M.-O., Fujii, Y., Umeyama, Y., Huang, B., Mariani, M., di Pietro, A., Choueiri, T.K.
Publicado 2022

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

por Choueiri, T. K., Motzer, R. J., Rini, B. I., Haanen, J., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J. L., Grimm, M.-O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Pal, S. K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., Albiges, L.
Publicado 2020